XBiotech/XBIT

$7.44

0.95%
-
1D1W1MYTD1YMAX

About XBiotech

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

Ticker

XBIT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Simard

Employees

92

Headquarters

Austin, United States

Website

-

XBiotech Metrics

BasicAdvanced
$238M
Market cap
-
P/E ratio
-$1.01
EPS
1.44
Beta
-
Dividend rate
$238M
1.4353
$9.96
$3.51
79K
12.027
4.778
-13.08%
-13.78%
-13.68%
1.136
1.137
-100%
1.85%

XBiotech Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$10M
117.39%
Profit margin
0%
NaN%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for XBiotech stock?

XBiotech (XBIT) has a market cap of $238M as of May 30, 2024.

What is the P/E ratio for XBiotech stock?

The price to earnings (P/E) ratio for XBiotech (XBIT) stock is 0 as of May 30, 2024.

Does XBiotech stock pay dividends?

No, XBiotech (XBIT) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next XBiotech dividend payment date?

XBiotech (XBIT) stock does not pay dividends to its shareholders.

What is the beta indicator for XBiotech?

XBiotech (XBIT) has a beta rating of 1.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the XBiotech stock price target?

The target price for XBiotech (XBIT) stock is $, which is 100% below the current price of $7.44. This is an average based on projections from analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell XBiotech stock

Buy or sell XBiotech stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing